INmune Bio Common Stock

INmune Bio (INMB) currently reports a common stock of $28K as of June 2026. That compares with $27K in the prior-year period — up 3.7% year over year. Use the charts on this page to explore INmune Bio's common stock history and peer comparisons.

INmune Bio's common stock increased from $27K to $28K — a 3.7% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

INmune Bio reported $28K in common stock as of June 2026. That compares with $27K in the prior-year period — up 3.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current common stock of $28K, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for INmune Bio, and consider following INMB for alerts when major investors trade the stock.

INmune Bio is classified in the Healthcare sector. On common stock, it currently shows $28K. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing INMB with unrelated industries.